411 related articles for article (PubMed ID: 26561015)
1. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
[TBL] [Abstract][Full Text] [Related]
2. Giant Prolactinoma in Men: Clinical Features and Therapeutic Outcomes.
Iglesias P; Arcano K; Berrocal VR; Bernal C; Villabona C; Díez JJ
Horm Metab Res; 2018 Nov; 50(11):791-796. PubMed ID: 30396208
[TBL] [Abstract][Full Text] [Related]
3. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
4. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
5. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
Chattopadhyay A; Bhansali A; Masoodi SR
Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
[TBL] [Abstract][Full Text] [Related]
7. Giant prolactinomas: the therapeutic approach.
Moraes AB; Silva CM; Vieira Neto L; Gadelha MR
Clin Endocrinol (Oxf); 2013 Oct; 79(4):447-56. PubMed ID: 23662975
[TBL] [Abstract][Full Text] [Related]
8. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
[TBL] [Abstract][Full Text] [Related]
9. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
10. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
[TBL] [Abstract][Full Text] [Related]
11. Giant prolactinomas: clinical management and long-term follow up.
Shrivastava RK; Arginteanu MS; King WA; Post KD
J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
[TBL] [Abstract][Full Text] [Related]
12. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
Tirosh A; Benbassat C; Shimon I
Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
[TBL] [Abstract][Full Text] [Related]
13. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
Burlacu MC; Maiter D; Duprez T; Delgrange E
Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
[TBL] [Abstract][Full Text] [Related]
14. Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR.
Sosa-Eroza E; Espinosa E; Ramírez-Rentería C; Mendoza V; Arreola R; Mercado M
Endocrine; 2018 Aug; 61(2):343-348. PubMed ID: 29948930
[TBL] [Abstract][Full Text] [Related]
15. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
16. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
[TBL] [Abstract][Full Text] [Related]
17. A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature.
Berwaerts J; Verhelst J; Abs R; Appel B; Mahler C
J Endocrinol Invest; 2000 Jun; 23(6):393-8. PubMed ID: 10908167
[TBL] [Abstract][Full Text] [Related]
18. Women with prolactinomas presented at the postmenopausal period.
Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
[TBL] [Abstract][Full Text] [Related]
19. Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.
Yang A; Cho SY; Park H; Kim MS; Kong DS; Shin HJ; Jin DK
Front Endocrinol (Lausanne); 2020; 11():527. PubMed ID: 32849307
[No Abstract] [Full Text] [Related]
20. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
